Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG3350 vs Senna after Urogynecologic Surgery
NCT06825260Phase 4Recruiting
- Sponsor
- St. Joseph's Health
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sennosides in constipation and obstructed defecation syndrome (ODS) (2 arms), sponsored by St. Joseph's Health. Primary endpoint: Postoperative Obstructed Defecation Syndrome at 7 days. Started Apr 2025; status: recruiting.
02
Drugs
sennosides
03
Conditions
constipationobstructed defecation syndrome (ODS)
Beyond the preview
Go deeper on NCT06825260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06825260.